Industry News

3 January 2026

Caplin Point strengthens U.S. footprint with strategic acquisition of 10 approved ANDAs

Caplin Point Laboratories Limited has announced a major strategic move to expand its presence in the regulated U.S. pharmaceutical market by acquiring ten approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic pharmaceuticals manufacturer.

27 December 2025

Zydus Life sciences strategic partnership with Bioeq for NUFYMCO

Bioeq AG, a Swiss biopharmaceutical company, and Zydus Lifesciences Limited , an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO® has been approved by U.S.

23 December 2025

Novo Nordisk Receives USFDA approval for Wegovy pill in the US

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.

19 December 2025

Pfizer & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India

Pfizer India and Cipla Limited announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.

18 December 2025

FDA approves RYBREVANT FASPRO™ : A first-of-its-kind subcutaneous therapy for EGFR-Mutated Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted approval to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), marking a significant advancement in the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer

16 December 2025

Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA is pleased to announce the upcoming launch1 of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial.

16 December 2025

Cipla launches Yurpeak (tirzepatide) for the treatment of Obesity and Type 2 Diabetes

Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak® — the second brand of Lilly’s tirzepatide in India, after Lilly received DCGI approval.

15 December 2025

Biocon Limited launches Liraglutide in the Netherlands

Biocon Limited an innovation-led global biopharmaceutical company, announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza®) and obesity (gSaxenda®), in the Netherlands through its distribution partner Pharmamedic B.V.

11 December 2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

Novo Nordisk and Akero Therapeutics Inc. announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.

11 December 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London.

Search

Caplin Point strengthens U.S. footprint with strategic acquisition of 10 approved ANDAs

RECOMMENDED POSTS

Subscribe with us

Jobs by Category